EP4058470A4 - Novel peptide compositions and methods of treating neurological injury - Google Patents

Novel peptide compositions and methods of treating neurological injury Download PDF

Info

Publication number
EP4058470A4
EP4058470A4 EP20887138.4A EP20887138A EP4058470A4 EP 4058470 A4 EP4058470 A4 EP 4058470A4 EP 20887138 A EP20887138 A EP 20887138A EP 4058470 A4 EP4058470 A4 EP 4058470A4
Authority
EP
European Patent Office
Prior art keywords
methods
novel peptide
peptide compositions
treating neurological
neurological injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20887138.4A
Other languages
German (de)
French (fr)
Other versions
EP4058470A2 (en
Inventor
Paco S. HERSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Publication of EP4058470A2 publication Critical patent/EP4058470A2/en
Publication of EP4058470A4 publication Critical patent/EP4058470A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20887138.4A 2019-11-15 2020-11-16 Novel peptide compositions and methods of treating neurological injury Pending EP4058470A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962936025P 2019-11-15 2019-11-15
PCT/US2020/060681 WO2021097407A2 (en) 2019-11-15 2020-11-16 Novel peptide compositions and methods of treating neurological injury

Publications (2)

Publication Number Publication Date
EP4058470A2 EP4058470A2 (en) 2022-09-21
EP4058470A4 true EP4058470A4 (en) 2024-02-28

Family

ID=75912490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20887138.4A Pending EP4058470A4 (en) 2019-11-15 2020-11-16 Novel peptide compositions and methods of treating neurological injury

Country Status (2)

Country Link
EP (1) EP4058470A4 (en)
WO (1) WO2021097407A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116891523B (en) * 2023-05-24 2024-05-17 深圳晶蛋生物医药科技有限公司 TRPM3 truncate, cell line containing same and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082053A2 (en) * 2006-01-10 2007-07-19 Trudeau Institute Trpm2-specific inhibitors
WO2017147298A1 (en) * 2016-02-23 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Peptide-based methods for treating neurological injury
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5703466B2 (en) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ Kinase inhibitors and uses thereof
WO2010115286A1 (en) * 2009-04-09 2010-10-14 Centre For Addiction And Mental Health Dopamine d2 receptor-disc1 interaction, compositions and methods for modulating same
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082053A2 (en) * 2006-01-10 2007-07-19 Trudeau Institute Trpm2-specific inhibitors
WO2017147298A1 (en) * 2016-02-23 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Peptide-based methods for treating neurological injury
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG YIHE ET AL: "Architecture of the TRPM2 channel and its activation mechanism by ADP-ribose and calcium", NATURE,, vol. 562, no. 7725, 24 September 2018 (2018-09-24), pages 145 - 149, XP036605649, DOI: 10.1038/S41586-018-0558-4 *

Also Published As

Publication number Publication date
WO2021097407A2 (en) 2021-05-20
EP4058470A2 (en) 2022-09-21
WO2021097407A3 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
EP3826666A4 (en) Compositions and methods for treating nrp2-associated diseases
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
EP3761970A4 (en) Compositions and methods for the treatment of neurological diseases
EP3810777A4 (en) Compositions and methods for the treatment and prevention of neurological disorders
EP3833340A4 (en) Compositions and methods for treatment of presbyopia
IL287802A (en) Compositions and methods for treatment of ocular diseases
EP3737355A4 (en) Compositions and methods for treating nerve injury
IL290891A (en) Compositions and methods of treating vascular diseases
EP4171606A4 (en) Compositions and methods for the treatment of covid-19
EP4003246A4 (en) Compositions and methods for treatment of presbyopia
EP3866790A4 (en) Methods and compositions for treatment of glaucoma and related conditions
EP4058470A4 (en) Novel peptide compositions and methods of treating neurological injury
EP4051260A4 (en) Methods and compositions for treatment of cancer
EP4017873A4 (en) Compositions and methods for the treatment of pathological pain and itch
EP3958876A4 (en) Compositions and methods for treatment of cancer
EP3735129A4 (en) Compositions and methods for treating neurological and other disorders
EP3911358A4 (en) Methods and compositions for treatment of cancer
EP4041390A4 (en) Compositions and methods for the treatment or prevention of traumatic brain injury
EP3836949A4 (en) Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
EP4087847A4 (en) Compositions and methods for the treatment of neurodegenerative diseases
EP3993833A4 (en) Compositions and methods for treating eye diseases
EP3743085A4 (en) Compositions and methods for treatment of spinal cord injury
EP3946302A4 (en) Methods and compositions for treating pain
EP3999076A4 (en) Compositions and methods for treating skin conditions
EP3927344A4 (en) Methods and compositions of treating an ophthalmic condition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240129

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20240123BHEP

Ipc: A61K 38/17 20060101ALI20240123BHEP

Ipc: A61K 47/64 20170101ALI20240123BHEP

Ipc: C07K 14/16 20060101ALI20240123BHEP

Ipc: C07K 14/47 20060101AFI20240123BHEP